Ranexa
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
The antianginal agent ranolazine (Ranexa®) is metabolized primarily by cytochrome P450‐3A (CYP3A) enzymes. Coadministration with…
Priority Application: US61/361056 Priority Date: July 2, 2010 Inventors: Kobayashi, Tetsuya; Koltun, Dmitry; Notte, Gregory…
Page 2487, column 2, section 2.2.1, paragraph 1, lines 14-19: The following sentence, which previously read: ‘‘There was no…
We report the case of a renal transplant patient on tacrolimus who developed a fully reversible renal failure and a doubling in…
Ischemic heart disease is the major cause of morbidity and mortality in the Western world. Patients often suffer a reduction in…
Ranolazine [Ranexa; (±)-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine] is novel anti-ischemic…
Ranolazine will provide a small benefit in symptom control in patients with chronic angina and persistent symptoms despite…
488 P&T® • September 2007 • Vol. 32 No. 9 INTRODUCTION Angina pectoris (chest pain) is a clinical syndrome characterized by…
(1) Ranolazine-- an adjunctive treatment to beta-blockers, calcium channel blockers, or long-acting nitrates-- is indicated for…
CV Therapeutics, under license from Roche (formerly Syntex), is developing ranolazine (Ranexa), a metabolic modulator and a…